Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014 (2014), Article ID 647541, 9 pages
http://dx.doi.org/10.1155/2014/647541
Review Article

Tumour Markers and Kidney Function: A Systematic Review

1Nephrology and Dialysis Unit, University Hospital “Magna Graecia”, 88100 Catanzaro, Italy
2CNR Institute of Clinical Physiology (IFC), 89100 Reggio Calabria, Italy

Received 16 August 2013; Revised 2 December 2013; Accepted 6 December 2013; Published 6 February 2014

Academic Editor: Shigeru Satoh

Copyright © 2014 Giuseppe Coppolino et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. B. Handy, “The clinical utility of tumor markers,” Laboratory Medicine, vol. 40, no. 2, pp. 99–103, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. J.-M. Bidart, F. Thuiller, C. Augereau et al., “Kinetics of serum tumor marker concentrations and usefulness in clinical monitoring,” Clinical Chemistry, vol. 45, no. 10, pp. 1695–1707, 1999. View at Google Scholar · View at Scopus
  3. L. M. McShane, D. G. Altman, W. Sauerbrei et al., “Reporting recommendations for tumor marker prognostic studies (REMARK),” Nature Clinical Practice Oncology, vol. 2, no. 8, pp. 416–422, 2005. View at Publisher · View at Google Scholar · View at Scopus
  4. D. G. Altman, L. M. McShane, W. Sauerbrei, and S. E. Taube, “Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration,” BMC Medicine, vol. 10, article 51, 2012. View at Publisher · View at Google Scholar
  5. M. Plebani, A. Giacomini, L. Beghi et al., “Serum tumor markers in monitoring patients: interpretation of results using analytical and biological variation,” Anticancer Research, vol. 16, no. 4B, pp. 2249–2252, 1996. View at Google Scholar · View at Scopus
  6. P. Maisonneuve, L. Agodoa, R. Gellert et al., “Cancer in patients on dialysis for end-stage renal disease: an international collaborative study,” The Lancet, vol. 354, no. 9173, pp. 93–99, 1999. View at Publisher · View at Google Scholar · View at Scopus
  7. P.-H. Weng, K.-Y. Hung, H.-L. Huang, J.-H. Chen, P.-K. Sung, and K.-C. Huang, “Cancer-specific mortality in chronic kidney disease: longitudinal follow-up of a large cohort,” Clinical Journal of the American Society of Nephrology, vol. 6, no. 5, pp. 1121–1128, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Buemi, A. Lacquaniti, D. Bolignano et al., “Dialysis and the elderly: an underestimated problem,” Kidney and Blood Pressure Research, vol. 31, no. 5, pp. 330–336, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Buemi, F. Floccari, C. Costa et al., “Dialysis-related genotoxicity: sister chromatid exchanges and DNA lesions in T and B lymphocytes of uremic patients. Genomic damage in patients on hemodiafiltration,” Blood Purification, vol. 24, no. 5-6, pp. 569–574, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Cases, X. Filella, R. Molina, A. M. Ballesta, J. Lopez-Pedret, and L. Revert, “Tumor markers in chronic renal failure and hemodialysis patients,” Nephron, vol. 57, no. 2, pp. 183–186, 1991. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Christensson, C.-B. Laurell, and H. Lilja, “Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors,” European Journal of Biochemistry, vol. 194, no. 3, pp. 755–763, 1990. View at Publisher · View at Google Scholar · View at Scopus
  12. M. C. Wang, L. A. Valenzuela, G. P. Murphy, and T. M. Chu, “Purification of a human prostate specific antigen,” Investigative Urology, vol. 17, no. 2, pp. 159–163, 1979. View at Google Scholar · View at Scopus
  13. G. Botchorishvili, M. P. Matikainen, and H. Lilja, “Early prostate-specific antigen changes and the diagnosis and prognosis of prostate cancer,” Current Opinion in Urology, vol. 19, no. 3, pp. 221–226, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. L. Bruun, C. Savage, A. M. Cronin, J. Hugosson, H. Lilja, and A. Christensson, “Increase in percent free prostate-specific antigen in men with chronic kidney disease,” Nephrology Dialysis Transplantation, vol. 24, no. 4, pp. 1238–1241, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. D. A. Joseph, T. Thompson, M. Saraiya, and D. M. Werny, “Association between glomerular filtration rate, free, total, and percent free prostate-specific antigen,” Urology, vol. 76, no. 5, pp. 1042–1046, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. A. Arican, N. Özdemir, S. Sezer et al., “Tumor markers in hemodialysis patients,” Transplantation Proceedings, vol. 31, no. 8, pp. 3367–3368, 1999. View at Google Scholar · View at Scopus
  17. N. Arik, B. Adam, T. Akpolat, K. Haşil, and S. Tabak, “Serum tumour markers in renal failure,” International Urology and Nephrology, vol. 28, no. 4, pp. 601–604, 1996. View at Publisher · View at Google Scholar · View at Scopus
  18. I. Tzanakis, S. Kazoulis, N. Girousis et al., “Prostate-specific antigen in hemodialysis patients and the influence of dialysis in its levels,” Nephron, vol. 90, no. 2, pp. 230–233, 2002. View at Publisher · View at Google Scholar · View at Scopus
  19. L. Bruun, T. Björk, H. Lilja, C. Becker, O. Gustafsson, and A. Christensson, “Percent-free prostate specific antigen is elevated in men on haemodialysis or peritoneal dialysis treatment,” Nephrology Dialysis Transplantation, vol. 18, no. 3, pp. 598–603, 2003. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Sumura, H. Yokogi, M. Beppu, and H. Honda, “Diagnostic value of serum prostate-specific antigen in hemodialysis patients,” International Journal of Urology, vol. 10, no. 5, pp. 247–250, 2003. View at Publisher · View at Google Scholar · View at Scopus
  21. Q. T. Khairullah, S. D. Pamatmat, M. Chatha, R. Provenzano, D. Telang, and M. Temple, “Early detection of prostate cancer in the ESRD population,” Clinical Nephrology, vol. 61, no. 5, pp. 308–315, 2004. View at Publisher · View at Google Scholar · View at Scopus
  22. Y. Wada, J. Nakanishi, W. Takahashi et al., “Mass screening for prostate cancer in patients with end-stage renal disease: a comparative study,” BJU International, vol. 98, no. 4, pp. 794–797, 2006. View at Publisher · View at Google Scholar · View at Scopus
  23. F. Tarhan, A. Orcun, I. Kucukercan, N. Camursoy, and U. Kuyumcuoglu, “Effect of hemodialysis on serum complexed prostate-specific antigen levels,” Scandinavian Journal of Urology, vol. 41, no. 5, pp. 382–386, 2007. View at Publisher · View at Google Scholar
  24. L. Bruun, H. Ekberg, T. Björk, H. Lilja, P. Höglund, and A. Christensson, “Rapid elimination by glomerular filtration of free prostate specific antigen and human kallikrein 2 after renal transplantation,” Journal of Urology, vol. 171, no. 4, pp. 1432–1435, 2004. View at Publisher · View at Google Scholar · View at Scopus
  25. L. Taupenot, K. L. Harper, and D. T. O'Connor, “The chromogranin-secretogranin family,” The New England Journal of Medicine, vol. 348, no. 12, pp. 1134–1149, 2003. View at Publisher · View at Google Scholar · View at Scopus
  26. L. Ferrari, E. Seregni, E. Bajetta, A. Martinetti, and E. Bombardieri, “The biological characteristics of chromogranin A and its role as a circulating marker in neuroendocrine tumours,” Anticancer Research, vol. 19, no. 4C, pp. 3415–3427, 1999. View at Google Scholar · View at Scopus
  27. A. Spadaro, A. Ajello, C. Morace et al., “Serum chromogranin-A in hepatocellular carcinoma: diagnostic utility and limits,” World Journal of Gastroenterology, vol. 11, no. 13, pp. 1987–1990, 2005. View at Google Scholar · View at Scopus
  28. R. J. Hsiao, R. J. Parmer, M. A. Takiyyuddin, and D. T. O'Connor, “Chromogranin A storage and secretion: sensitivity and specificity for the diagnosis of pheochromocytoma,” Medicine, vol. 70, no. 1, pp. 33–45, 1991. View at Publisher · View at Google Scholar · View at Scopus
  29. R. M. Salem, P. E. Cadman, Y. Chen et al., “Chromogranin A polymorphisms are associated with hypertensive renal disease,” Journal of the American Society of Nephrology, vol. 19, no. 3, pp. 600–614, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. M. A. Takiyyuddin, J. H. Cervenka, R. J. Hsiao, J. A. Barbosa, R. J. Parmer, and D. T. O'Connor, “Chromogranin A. Storage and release in hypertension,” Hypertension, vol. 15, no. 3, pp. 237–246, 1990. View at Publisher · View at Google Scholar · View at Scopus
  31. R. J. Hsiao, M. S. Mezger, and D. T. O'Connor, “Chromogranin A in uremia: progressive retention of immunoreactive fragments,” Kidney International, vol. 37, no. 3, pp. 955–964, 1990. View at Publisher · View at Google Scholar · View at Scopus
  32. G. Tramonti, M. Ferdeghini, C. Annichiarico et al., “Relationship between renal function and blood level of chromogranin A,” Renal Failure, vol. 23, no. 3-4, pp. 449–457, 2001. View at Publisher · View at Google Scholar · View at Scopus
  33. G. Castoldi, L. Antolini, C. Bombardi et al., “Oxidative stress biomarkers and chromogranin A in uremic patients: effects of dialytic treatment,” Clinical Biochemistry, vol. 43, no. 18, pp. 1387–1392, 2010. View at Publisher · View at Google Scholar · View at Scopus
  34. T. B. Tomasi Jr., “Structure and function of alpha-fetoprotein,” Annual Review of Medicine, vol. 28, pp. 453–465, 1977. View at Publisher · View at Google Scholar · View at Scopus
  35. G. J. Mizejewski, “Biological roles of alpha-fetoprotein during pregnancy and perinatal development,” Experimental Biology and Medicine, vol. 229, no. 6, pp. 439–463, 2004. View at Google Scholar · View at Scopus
  36. C. R. Nichols, “Testicular cancer,” Current Problems in Cancer, vol. 22, no. 4, pp. 187–274, 1998. View at Publisher · View at Google Scholar
  37. W. C. Lye, P. Tambyah, S. O. Leong, and E. J. Lee, “Serum tumor markers in patients on dialysis and kidney transplantation,” Advances in Peritoneal Dialysis, vol. 10, pp. 109–111, 1994. View at Google Scholar · View at Scopus
  38. C. Rosano, S. Zuccotti, and M. Bolognesi, “The three-dimensional structure of β2 microglobulin: results from X-ray crystallography,” Biochimica et Biophysica Acta, vol. 1753, no. 1, pp. 85–91, 2005. View at Publisher · View at Google Scholar · View at Scopus
  39. C. Vincent and J. P. Revillard, “Beta-2-microglobulin and HLA-related glycoproteins in human urine and serum,” Contributions to Nephrology, vol. 26, pp. 66–88, 1981. View at Google Scholar · View at Scopus
  40. D. Rossi, M. Fangazio, L. De Paoli et al., “Beta-2-microglobulin is an independent predictor of progression in asymptomatic multiple myeloma,” Cancer, vol. 116, no. 9, pp. 2188–2200, 2010. View at Publisher · View at Google Scholar · View at Scopus
  41. M. Bethea and D. T. Forman, “β2-Microglobulin: its significance and clinical usefulness,” Annals of Clinical & Laboratory Science, vol. 20, no. 3, pp. 163–168, 1990. View at Google Scholar · View at Scopus
  42. A.-M. Tsimberidou, H. M. Kantarjian, S. Wen et al., “The prognostic significance of serum β2 microglobulin levels in acute myeloid leukemia and prognostic scores predicting survival: analysis of 1,180 patients,” Clinical Cancer Research, vol. 14, no. 3, pp. 721–730, 2008. View at Publisher · View at Google Scholar · View at Scopus
  43. S. Josson, T. Nomura, J.-T. Lin et al., “β2-microglobulin induces epithelial to mesenchymal transition and confers cancer lethality and bone metastasis in human cancer cells,” Cancer Research, vol. 71, no. 7, pp. 2600–2610, 2011. View at Publisher · View at Google Scholar · View at Scopus
  44. A. K. Cheung, M. V. Rocco, G. Yan et al., “Serum β-2 microglobulin levels predict mortality in dialysis patients: results of the HEMO study,” Journal of the American Society of Nephrology, vol. 17, no. 2, pp. 546–555, 2006. View at Publisher · View at Google Scholar · View at Scopus
  45. S. Liabeuf, A. Lenglet, L. Desjardins et al., “Plasma beta-2 microglobulin is associated with cardiovascular disease in uremic patients,” Kidney International, vol. 82, no. 12, pp. 1297–1303, 2012. View at Publisher · View at Google Scholar
  46. T. B. Drüeke and Z. A. Massy, “Beta2-microglobulin,” Seminars in Dialysis, vol. 22, no. 4, pp. 378–380, 2009. View at Publisher · View at Google Scholar · View at Scopus
  47. J. Floege and G. Ehlerding, “Beta-2-microglobulin-associated amyloidosis,” Nephron, vol. 72, no. 1, pp. 9–26, 1996. View at Publisher · View at Google Scholar · View at Scopus
  48. M. Y. Porter, K. E. Routledge, S. E. Radford, and E. W. Hewitt, “Characterization of the response of primary cells relevant to dialysis-related amyloidosis to β2-microglobulin monomer and fibrils,” PLoS ONE, vol. 6, no. 11, Article ID e27353, 2011. View at Publisher · View at Google Scholar · View at Scopus
  49. R. A. Odell, P. Slowiaczek, J. E. Moran, and K. Schindhelm, “Beta 2-microglobulin kinetics in end-stage renal failure,” Kidney International, vol. 39, no. 5, pp. 909–919, 1991. View at Publisher · View at Google Scholar · View at Scopus
  50. J. M. Campistol, “Dialysis-related amyloidosis after renal transplantation,” Seminars in Dialysis, vol. 14, no. 2, pp. 99–102, 2001. View at Publisher · View at Google Scholar · View at Scopus
  51. J.-L. Mege, C. Capo, R. Purgus, and M. Olmer, “Monocyte production of transforming growth factor β in longterm hemodialysis: modulation by hemodialysis membranes,” American Journal of Kidney Diseases, vol. 28, no. 3, pp. 395–399, 1996. View at Publisher · View at Google Scholar · View at Scopus
  52. C. Küchle, H. Fricke, E. Held, and H. Schiffl, “High-flux hemodialysis postpones clinical manifestation of dialysis-related amyloidosis,” American Journal of Nephrology, vol. 16, no. 6, pp. 484–488, 1996. View at Publisher · View at Google Scholar · View at Scopus
  53. J. Delgado, G. Pratt, N. Phillips et al., “Beta 2-microglobulin is a better predictor of treatment-free survival in patients with chronic lymphocytic leukaemia if adjusted according to glomerular filtration rate,” British Journal of Haematology, vol. 145, no. 6, pp. 801–805, 2009. View at Publisher · View at Google Scholar · View at Scopus
  54. M. Brayman, A. Thathiah, and D. D. Carson, “MUC1: a multifunctional cell surface component of reproductive tissue epithelia,” Reproductive Biology and Endocrinology, vol. 2, article 4, 2004. View at Publisher · View at Google Scholar · View at Scopus
  55. D. B. Vimal, M. Khullar, S. Gupta, and N. K. Ganguly, “Intestinal mucins: the binding sites for Salmonella typhimurium,” Molecular and Cellular Biochemistry, vol. 204, no. 1-2, pp. 107–117, 2000. View at Publisher · View at Google Scholar · View at Scopus
  56. I. Brockhausen, J.-M. Yang, J. Burchell, C. Whitehouse, and J. Taylor-Papadimitriou, “Mechanisms underlying aberrant glycosylation of MUC1 mucin in breast cancer cells,” European Journal of Biochemistry, vol. 233, no. 2, pp. 607–617, 1995. View at Publisher · View at Google Scholar · View at Scopus
  57. M. J. Duffy, D. Evoy, and E. W. McDermott, “CA 15-3: uses and limitation as a biomarker for breast cancer,” Clinica Chimica Acta, vol. 411, no. 23-24, pp. 1869–1874, 2010. View at Publisher · View at Google Scholar · View at Scopus
  58. D. Al-Azawi, G. Kelly, E. Myers et al., “CA 15-3 is predictive of response and disease recurrence following treatment in locally advanced breast cancer,” BMC Cancer, vol. 6, article 220, 2006. View at Publisher · View at Google Scholar · View at Scopus
  59. F. G. Ebeling, P. Stieber, M. Untch et al., “Serum CEA and CA 15–3 as prognostic factors in primary breast cancer,” British Journal of Cancer, vol. 86, no. 8, pp. 1217–1222, 2002. View at Publisher · View at Google Scholar · View at Scopus
  60. M. Gion, P. Boracchi, R. Dittadi et al., “Prognostic role of serum CA15.3 in 362 node-negative breast cancers. an old player for a new game,” European Journal of Cancer, vol. 38, no. 9, pp. 1181–1188, 2002. View at Publisher · View at Google Scholar · View at Scopus
  61. A. Martín, M. D. Corte, A. M. Álvarez et al., “Prognostic value of pre-operative serum CA 15.3 levels in breast cancer,” Anticancer Research, vol. 26, no. 5B, pp. 3965–3971, 2006. View at Google Scholar · View at Scopus
  62. X. Filella, A. Cases, R. Molina et al., “Tumor markers in patients with chronic renal failure,” The International Journal of Biological Markers, vol. 5, no. 2, pp. 85–88, 1990. View at Google Scholar · View at Scopus
  63. N. Zeferos, G. E. Digenis, M. Christophoraki, I. Alexopoulos, A. H. Kostakis Gyftaki, and S. Moulopoulos, “Tumor markers in patients undergoing hemodialysis or kidney transplantation,” Nephron, vol. 59, no. 4, pp. 618–620, 1991. View at Publisher · View at Google Scholar · View at Scopus
  64. G. Tzitzikos, M. Saridi, T. Filippopoulou et al., “Measurement of tumor markers in chronic hemodialysis patients,” Saudi Journal of Kidney Diseases and Transplantation, vol. 21, no. 1, pp. 50–53, 2010. View at Google Scholar · View at Scopus
  65. Y. Xiaofang, Z. Yue, X. Xialian, and Y. Zhibin, “Serum tumour markers in patients with chronic kidney disease,” Scandinavian Journal of Clinical & Laboratory Investigation, vol. 67, no. 6, pp. 661–667, 2007. View at Publisher · View at Google Scholar · View at Scopus
  66. B. W. T. Yin and K. O. Lloyd, “Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16,” Journal of Biological Chemistry, vol. 276, no. 29, pp. 27371–27375, 2001. View at Publisher · View at Google Scholar · View at Scopus
  67. B. H. Perez and I. K. Gipson, “Focus on molecules: human mucin MUC16,” Experimental Eye Research, vol. 87, no. 5, pp. 400–401, 2008. View at Publisher · View at Google Scholar · View at Scopus
  68. B. W. J. Mol, N. Bayram, J. G. Lijmer et al., “The performance of CA-125 measurement in the detection of endometriosis: a meta-analysis,” Fertility and Sterility, vol. 70, no. 6, pp. 1101–1108, 1998. View at Publisher · View at Google Scholar · View at Scopus
  69. H. Devarbhavi, D. Kaese, A. W. Williams, J. Rakela, G. G. Klee, and P. S. Kamath, “Cancer antigen 125 in patients with chronic liver disease,” Mayo Clinic Proceedings, vol. 77, no. 6, pp. 538–541, 2002. View at Publisher · View at Google Scholar · View at Scopus
  70. O. Topalak, U. Saygili, M. Soyturk et al., “Serum, pleural effusion, and ascites CA-125 levels in ovarian cancer and nonovarian benign and malignant diseases: a comparative study,” Gynecologic Oncology, vol. 85, no. 1, pp. 108–113, 2002. View at Publisher · View at Google Scholar · View at Scopus
  71. A. P. Singh, S. Senapati, M. P. Ponnusamy et al., “Clinical potential of mucins in diagnosis, prognosis, and therapy of ovarian cancer,” The Lancet Oncology, vol. 9, no. 11, pp. 1076–1085, 2008. View at Publisher · View at Google Scholar · View at Scopus
  72. L. R. Medeiros, D. D. Rosa, M. I. da Rosa, and M. C. Bozzetti, “Accuracy of CA 125 in the diagnosis of ovarian tumors: a quantitative systematic review,” European Journal of Obstetrics & Gynecology Reproductive Biology, vol. 142, no. 2, pp. 99–105, 2009. View at Publisher · View at Google Scholar · View at Scopus
  73. K. Sjövall, B. Nilsson, and N. Einhorn, “The significance of serum CA 125 elevation in malignant and nonmalignant diseases,” Gynecologic Oncology, vol. 85, no. 1, pp. 175–178, 2002. View at Publisher · View at Google Scholar · View at Scopus
  74. K. J. Carlson, S. J. Skates, and D. E. Singer, “Screening for ovarian cancer,” Annals of Internal Medicine, vol. 121, no. 2, pp. 124–132, 1994. View at Publisher · View at Google Scholar · View at Scopus
  75. H. Meden and A. Fattani-Meiodi, “CA 125 in benign gynecological conditions,” International Journal of Biological Markers, vol. 13, no. 4, pp. 231–237, 1998. View at Google Scholar · View at Scopus
  76. A. W. Menzin, S. Kobrin, E. Pollak, D. B. P. Goodman, and S. C. Rubin, “The effect of renal function on serum levels of CA 125,” Gynecologic Oncology, vol. 58, no. 3, pp. 375–377, 1995. View at Publisher · View at Google Scholar · View at Scopus
  77. S. S. Buys, E. Partridge, A. Black et al., “Effect of screening on ovarian cancer mortality: the prostate, lung, colorectal and ovarian (PLCO) cancer screening randomized controlled trial,” The Journal of the American Medical Association, vol. 305, no. 22, pp. 2295–2302, 2011. View at Publisher · View at Google Scholar · View at Scopus
  78. M. J. Mojahedi, M. Hami, M.-T. Shakeri, and R. Hekmat, “Influence of dialysis duration, peritoneal transport parameters, and gender on effluent CA125 concentration in patients on peritoneal dialysis,” Iranian Journal of Kidney Diseases, vol. 1, no. 2, pp. 78–81, 2007. View at Google Scholar · View at Scopus
  79. M. Ugorski and A. Laskowska, “Sialyl Lewisa: a tumor-associated carbohydrate antigen involved in adhesion and metastatic potential of cancer cells,” Acta Biochimica Polonica, vol. 49, no. 2, pp. 303–311, 2002. View at Google Scholar · View at Scopus
  80. E. Waanders, L. van Keimpema, J. T. Brouwer et al., “Carbohydrate antigen 19–9 is extremely elevated in polycystic liver disease,” Liver International, vol. 29, no. 9, pp. 1389–1395, 2009. View at Publisher · View at Google Scholar · View at Scopus
  81. G. Y. Locker, S. Hamilton, J. Harris et al., “ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer,” Journal of Clinical Oncology, vol. 24, no. 33, pp. 5313–5327, 2006. View at Publisher · View at Google Scholar · View at Scopus
  82. S. Fritz, T. Hackert, U. Hinz, W. Hartwig, M. W. Büchler, and J. Werner, “Role of serum carbohydrate antigen 19-9 and carcinoembryonic antigen in distinguishing between benign and invasive intraductal papillary mucinous neoplasm of the pancreas,” British Journal of Surgery, vol. 98, no. 1, pp. 104–110, 2011. View at Publisher · View at Google Scholar · View at Scopus
  83. E. I. Kohorn, “The new FIGO 2000 staging and risk factor scoring system for gestational trophoblastic disease: description and critical assessment,” International Journal of Gynecological Cancer, vol. 11, no. 1, pp. 73–77, 2001. View at Publisher · View at Google Scholar · View at Scopus
  84. E. A. Klein, “Tumor markers in testis cancer,” Urologic Clinics of North America, vol. 20, no. 1, pp. 67–73, 1993. View at Google Scholar · View at Scopus
  85. J. J. Gregory Jr. and J. L. Finlay, “α-fetoprotein and β-human chorionic gonadotropin. their clinical significance as tumour markers,” Drugs, vol. 57, no. 4, pp. 463–467, 1999. View at Publisher · View at Google Scholar · View at Scopus
  86. B. C. Nisula, D. L. Blithe, A. Akar, G. Lefort, and R. E. Wehmann, “Metabolic fate of human choriogonadotropin,” Journal of Steroid Biochemistry, vol. 33, no. 4B, pp. 733–737, 1989. View at Publisher · View at Google Scholar · View at Scopus
  87. R. E. Wehmann and B. C. Nisula, “Metabolic and renal clearance rates of purified human chorionic gonadotropin,” Journal of Clinical Investigation, vol. 68, no. 1, pp. 184–194, 1981. View at Publisher · View at Google Scholar · View at Scopus